GalNAc-siRNA Conjugates Market - Global Forecast 2026-2032

The GalNAc-siRNA conjugates market is entering a critical phase, driven by advances in delivery chemistry, manufacturing scalability, and clinical application diversity. Senior stakeholders are navigating intensifying competition, operational shifts, and evolving global regulatory landscapes.

Market Snapshot: GalNAc-siRNA Conjugates Market Overview

The GalNAc-siRNA conjugates market grew from USD 671.21 million in 2025 to USD 729.96 million in 2026 and is expected to continue expanding at a CAGR of 7.38%, reaching USD 1.10 billion by 2032. This sustained growth reflects increasing demand for RNA interference therapies and continuous software and manufacturing innovation across global regions. Investors and executives seek actionable intelligence to guide development, supply chain management, and competitive strategy amid rapid market evolution.

Scope & Segmentation of the GalNAc-siRNA Conjugates Market

Product Types: Late-stage, clinically validated assets with established dosing alongside early-stage candidates emphasizing novel conjugation chemistry or emerging target biology.
Therapeutic Areas: Focus centers on cardiometabolic and hepatology indications, rare genetic and complement-driven disorders, as well as expanded investigation in viral infections and more complex hepatology.
End Users: Hospitals, specialty clinics, research institutes, academic centers, pharmaceutical companies, and biotechnology developers each shape distinct adoption and operational pathways for these therapies.
Distribution Channels: Strategies encompass specialty pharmacy distribution, hospital-based procurement, and supply models enabling integrated patient services and efficient logistics.
Regions: Coverage includes Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique market access, regulatory, and supply chain considerations.
Technologies: Platform manufacturing, refined chemical stabilization, class-specific safety protocols, and next-generation conjugate architectures underpin differentiation and scalability.

Key Takeaways: Strategic Insights for Decision-Makers

Durability and predictable silencing are central to competitive positioning, with chemistry and delivery innovations enabling broader applications beyond rare liver diseases.
Platform manufacturing is becoming essential, redefining how companies partner with CDMOs and manage process scalability and analytical lifecycle management.
Clinical development now emphasizes class-specific safety monitoring, robust biomarker integration, and agile approaches to dose and indication selection.
Cross-modality competition from antisense oligonucleotides, gene editing, and mRNA therapies pushes companies to clearly articulate GalNAc-siRNA value around redosing and tissue selectivity.
Supply chain resilience, especially in response to fluctuating policy and international events, is increasingly prioritized as an operational and strategic pillar.
Sponsors with integrated partnerships—spanning manufacturing, analytics, and regulatory support—can decisively accelerate commercialization and address critical knowledge and capacity gaps.

Tariff Impact: Navigating U.S. Policy Shifts and Supply Chain Volatility

U.S. tariffs anticipated in 2025 present new operational uncertainties for GalNAc-siRNA conjugates, as the value chain relies on specialized reagents, instruments, and complex cross-border manufacturing. Tariffs may raise landed costs, disrupt batch scheduling, and force sponsors to requalify suppliers. This increases regulatory and technical burdens, particularly for late-stage products sensitive to raw material variations. Forward-thinking organizations are incorporating tariff exposure into enterprise risk management, emphasizing supply chain scenario planning and domestic or tariff-resilient manufacturing investment. Smaller players may encounter new barriers, making tariff strategy inseparable from broader partnering models and negotiations.

Methodology & Data Sources

This report integrates comprehensive secondary research, analyzing regulatory documentation, clinical trial registries, peer-reviewed literature, patents, and company disclosures. Primary research includes interviews across the biopharma value chain, focusing on CMC specialists, manufacturing experts, and executive perspectives. Triangulation validates strategic findings and identifies actionable trends, aligning results with evolving policy, clinical, and operational realities.

Why This Report Matters

Gain clarity on the drivers shaping competitive advantage in GalNAc-siRNA conjugates and how platform maturity is influencing market leadership.
Understand critical risks and scenarios in supply chain resilience and tariff exposure, offering executive-level guidance for industrialization and partnership decisions.
Leverage actionable insights on segmentation and regional dynamics to align product, operational, and go-to-market strategies for long-term value creation.

Conclusion

GalNAc-siRNA conjugates are transitioning from scientific proof-of-concept to operational discipline, reshaping value across delivery, manufacturing, and care pathways. Strategic alignment between science, operations, and regional access will define leadership as the market matures.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-siRNA Conjugates Market, by Product Type

8.1. Biantennary
8.2. Monoantennary
8.3. Triantennary

9. GalNAc-siRNA Conjugates Market, by Indication

9.1. Acute Hepatic Porphyria
9.2. Homozygous Familial Hypercholesterolemia
9.3. Primary Hyperoxaluria Type 1
9.4. Transthyretin-Mediated Amyloidosis

10. GalNAc-siRNA Conjugates Market, by Formulation

10.1. Lyophilized Powder
10.2. Solution

11. GalNAc-siRNA Conjugates Market, by End User

11.1. Hospitals
11.2. Research Organizations
11.3. Specialty Clinics

12. GalNAc-siRNA Conjugates Market, by Distribution Channel

12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies

13. GalNAc-siRNA Conjugates Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. GalNAc-siRNA Conjugates Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. GalNAc-siRNA Conjugates Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States GalNAc-siRNA Conjugates Market
17. China GalNAc-siRNA Conjugates Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Akcea Therapeutics, Inc.
18.6. Alnylam Pharmaceuticals, Inc.
18.7. Amgen Inc.
18.8. Arcturus Therapeutics Holdings Inc.
18.9. Arrowhead Pharmaceuticals, Inc.
18.10. AstraZeneca plc
18.11. Bayer AG
18.12. Beam Therapeutics Inc.
18.13. BioNTech SE
18.14. CureVac N.V.
18.15. Dicerna Pharmaceuticals, Inc.
18.16. Eli Lilly and Company
18.17. Gilead Sciences, Inc.
18.18. GlaxoSmithKline plc
18.19. Ionis Pharmaceuticals, Inc.
18.20. Merck & Co., Inc.
18.21. Moderna, Inc.
18.22. Novartis AG
18.23. Novo Nordisk A/S
18.24. Pfizer Inc.
18.25. Roche Holding AG
18.26. Sanofi S.A.
18.27. Sarepta Therapeutics, Inc.
18.28. Takeda Development Center Americas, Inc.
18.29. Takeda Pharmaceutical Company Limited

List of Figures

FIGURE 1. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 67. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 79. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 80. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 81. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 91. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 93. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 104. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 105. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 106. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 111. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 112. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 122. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 123. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 124. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 128. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 130. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 134. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 136. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 141. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 147. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 149. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this GalNAc-siRNA Conjugates market report include:

Akcea Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arcturus Therapeutics Holdings Inc.
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
Bayer AG
Beam Therapeutics Inc.
BioNTech SE
CureVac N.V.
Dicerna Pharmaceuticals, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
GlaxoSmithKline plc
Ionis Pharmaceuticals, Inc.
Merck & Co., Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Sarepta Therapeutics, Inc.
Takeda Development Center Americas, Inc.
Takeda Pharmaceutical Company Limited

Table Information

Report Attribute	Details
No. of Pages	195
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 729.96 Million
Forecasted Market Value ( USD ) by 2032	$ 1100 Million
Compound Annual Growth Rate	7.3%
Regions Covered	Global
No. of Companies Mentioned	26

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: GalNAc-siRNA Conjugates Market Overview

Scope & Segmentation of the GalNAc-siRNA Conjugates Market

Key Takeaways: Strategic Insights for Decision-Makers

Tariff Impact: Navigating U.S. Policy Shifts and Supply Chain Volatility

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Reports

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032

GalNac Conjugates Market - Global Forecast 2025-2030

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

RNAi Technology Market - Global Strategic Business Report